Management of hepatitis C virus (HCV) infection in drug substitution programs

Publikation

Management of hepatitis C virus (HCV) infection in drug substitution programs

Wissenschaftlicher Artikel/Review - 27.05.2011

Witteck Andrea, Schmid Patrick, Hensel-Koch K, Thurnheer M C, Bruggmann P, Vernazza Pietro

Zitation

Witteck A, Schmid P, Hensel-Koch K, Thurnheer M, Bruggmann P, Vernazza P. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly 2011; 141:w13193.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Swiss Med Wkly 2011; 141

Veröffentlichungsdatum

27.05.2011

eISSN (Online)

1424-3997

Seiten

w13193

Kurzbeschreibung/Zielsetzung

In Switzerland, intravenous drug use (IDU) accounts for 80% of newly acquired hepatitis C virus (HCV) infections. Early HCV treatment has the potential to interrupt the transmission chain and reduce morbidity/mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programs are often insufficiently screened and treated.